Invention Grant
- Patent Title: Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same
-
Application No.: US16610278Application Date: 2018-04-25
-
Publication No.: US11352399B2Publication Date: 2022-06-07
- Inventor: Sang Dun Choi , Hyuk Kwon Kwon , Hyeon Jun Shin , Xiang Ai Gui
- Applicant: GENESEN CO., LTD.
- Applicant Address: KR Seoul
- Assignee: GENESEN CO., LTD.
- Current Assignee: GENESEN CO., LTD.
- Current Assignee Address: KR Seoul
- Agency: Sughrue Mion, PLLC
- Priority: KR10-2017-0056842 20170504,KR10-2018-0046715 20180423
- International Application: PCT/KR2018/004803 WO 20180425
- International Announcement: WO2018/203613 WO 20181108
- Main IPC: C07K7/08
- IPC: C07K7/08 ; C07K14/435 ; C07K14/475 ; A61K38/10 ; A61K38/17 ; A61K38/18 ; C07K14/705 ; C07K14/47 ; C07K16/24 ; C07K16/28 ; A61K38/00 ; C07K14/71
Abstract:
The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.
Information query
